文献速递肝胆胰外科

新辅助治疗与直接手术治疗可切除胰腺腺癌的全国倾向评分匹配分析

Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis.
PubMed 文献 · Surgery · 2016-10-27

该回顾性队列研究基于美国国家癌症数据库2004至2012年数据,纳入接受胰腺切除并启动化疗的非转移性胰腺腺癌患者,采用倾向评分匹配比较新辅助治疗与直接手术的生存差异。结果显示新辅助治疗的生存获益与临床分期相关:在临床III期患者中显著延长生存,而在I期和II期患者中两种治疗顺序的生存无差异。

要点

  • 新辅助治疗对可切除胰腺癌的生存影响呈分期依赖性。
  • 临床III期患者新辅助治疗后中位生存22.9个月,优于直接手术的17.3个月。
  • 临床I期和II期患者中,新辅助治疗与直接手术的生存无显著差异。

核心结论

  • 新辅助治疗的生存影响具有分期依赖性,在III期胰腺癌中与显著生存优势相关,在I期和II期未显示生存差异,且在任何分期均不劣于传统直接手术加辅助治疗。

研究设计与样本

  • 回顾性队列研究,使用2004至2012年美国国家癌症数据库,纳入接受胰腺切除并启动化疗的非转移性胰腺腺癌患者。
  • 共1,541例接受新辅助治疗后手术,7,159例接受直接手术后辅助治疗。
  • 在每个临床分期内部进行倾向评分匹配以控制选择偏倚,采用Kaplan-Meier法比较总生存。

主要发现

  • 临床III期患者(n=486)匹配后,新辅助治疗组中位生存22.9个月,直接手术组17.3个月,log-rank P < .0001。
  • 临床I期患者(n=3,149)匹配后,新辅助治疗组中位生存26.2个月,直接手术组25.7个月,P = .4418。
  • 临床II期患者(n=5,065)匹配后,新辅助治疗组中位生存23.5个月,直接手术组23.0个月,P = .7751。

临床怎么用

  • 对于临床III期可切除胰腺腺癌患者,可考虑新辅助治疗以改善生存。
  • 对于临床I期和II期患者,新辅助治疗不劣于直接手术,但未显示额外生存获益,治疗决策需个体化。

局限性

  • 本研究为回顾性队列研究,尽管采用倾向评分匹配,仍可能存在未测量的混杂因素。
  • 缺乏随机对照试验证据,新辅助治疗在可切除胰腺癌中的作用尚存争议。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant therapy is an emerging paradigm in pancreatic cancer care; however, its role for resectable disease remains controversial in the absence of conclusive randomized controlled trials. The purpose of the present study is to assess the impact of neoadjuvant therapy on survival in resected pancreatic cancer patients by clinical stage. METHODS: A retrospective cohort study using the National Cancer Data Base from 2004 to 2012 including nonmetastatic pancreatic adenocarcinoma patients who underwent pancreatectomy and initiated chemotherapy. Propensity score matching within each stage was used to account for potential selection bias between patients undergoing neoadjuvant therapy and upfront surgery. Overall survival was compared by the Kaplan-Meier method. RESULTS: In the study, 1,541 and 7,159 patients received neoadjuvant therapy followed by surgery and upfront surgery succeeded by adjuvant therapy, respectively. In clinical stage III pancreatic cancer (n = 486), neoadjuvant therapy was associated with significant survival benefit after matching (median survival 22.9 vs 17.3 months; log-rank P < .0001) compared with conventional upfront surgery followed by adjuvant therapy; however, no survival difference was found between the 2 treatment sequences in patients with clinical stage I (n = 3,149; median survival, 26.2 vs 25.7 months; P = .4418) and II (n = 5,065; median survival, 23.5 vs 23.0 months; P = .7751) disease after matching. CONCLUSION: The survival impact of neoadjuvant therapy is stage-dependent. Neoadjuvant therapy does not disadvantage survival compared with conventional upfront surgery followed by adjuvant therapy in any stage, and is associated with a significant survival advantage in stage III pancreatic cancer.

来源:Surgery,查看原文。版权归原作者所有。

引用

  1. de Geus SW, Eskander MF, Bliss LA, et al. Neoadjuvant therapy versus upfront surgery for resected pancreatic adenocarcinoma: A nationwide propensity score matched analysis. Surgery. 2016. PMID: 28341441. doi:10.1016/j.surg.2016.08.040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。